Although targeting the IL-23/17 axis is effective in spondyloarthritis49, strategies to block the IL-17 pathway, IL-12/23 p40, or IL-23 did not prove to be effective in patients with established RA, and the clinical research programs in RA were discontinued50. The gene discussed is IL17A; the disease is rheumatoid arthritis.